M Usami

ORCID: 0000-0001-8206-1285
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Prostate Cancer Treatment and Research
  • Cancer, Lipids, and Metabolism
  • Kawasaki Disease and Coronary Complications
  • Autoimmune and Inflammatory Disorders Research
  • Bladder and Urothelial Cancer Treatments
  • Microscopic Colitis
  • Inflammatory Bowel Disease
  • Renal cell carcinoma treatment
  • Neuroscience and Neuropharmacology Research
  • Urinary and Genital Oncology Studies
  • Colorectal Cancer Treatments and Studies
  • Tuberculosis Research and Epidemiology
  • Immunodeficiency and Autoimmune Disorders
  • Testicular diseases and treatments
  • Urologic and reproductive health conditions
  • Urological Disorders and Treatments
  • Alzheimer's disease research and treatments
  • Prostate Cancer Diagnosis and Treatment
  • Pregnancy and Medication Impact
  • Monoclonal and Polyclonal Antibodies Research
  • Coronary Artery Anomalies
  • Signaling Pathways in Disease
  • Glioma Diagnosis and Treatment
  • COVID-19 Impact on Reproduction
  • Prion Diseases and Protein Misfolding

Kanazawa University Hospital
2023-2024

Kanazawa University
2009-2023

National Center For Child Health and Development
2021-2022

Sapporo Medical University
2009

Kobe University
2009

Yamagata University
2009

Kyushu University
2009

Hokkaido University
2009

University of Tsukuba
1994-2009

Nagasaki University
2009

We have biochemically purified A beta from brains of two unrelated familial Alzheimer's disease (FAD) pedigrees with the APP717 mutation (Val-->Ile) and sporadic (AD) characterized them by means mass spectrometry enzyme-linked immunosorbent assay. observed types amyloid protein (A beta), short-tail form 1-40) long-tail 1-42/43), in AD FAD brains, found that ratio 1-42/43) to total was increased brains. These vivo results were confirmed vitro using cultured cells transfected three kinds APP...

10.1016/s0021-9258(20)30050-8 article EN cc-by Journal of Biological Chemistry 1994-12-01

Abstract Objectives To compare the cytokines involved in development of macrophage activation syndrome (MAS) different background rheumatic diseases and to identify serum biomarkers for MAS diagnosis. Methods Serum neopterin, IL-6, IL-18 soluble TNF receptor (sTNFR) type I (sTNFR-I) II (sTNFR-II) levels were determined using ELISA 12 patients with SLE, including five MAS; JDM, four 75 Kawasaki disease (KD), six 179 systemic JIA (s-JIA), 43 MAS. These results compared clinical features...

10.1093/rheumatology/keaa299 article EN Lara D. Veeken 2020-05-30

Very early-onset inflammatory bowel disease (VEO-IBD), defined as IBD diagnosed in patients younger than 6 years, is a challenge for pediatric gastroenterologists. Although there have been reports regarding VEO-IBD Western countries, those Asia are still lacking. This study aimed to investigate the clinical features of Japanese patients.Patients with between 2006 and 2019 were evaluated retrospectively. The phenotypes classified into ulcerative colitis type (UC-type) Crohn's (CD-type),...

10.5217/ir.2021.00142 article EN cc-by-nc Intestinal Research 2022-06-10

Several mutations of presenilin (PS)-1, 2 result in early onset Alzheimer disease. Using the yeast two-hybrid system, interaction between PS2 loop domain and C-terminal region mu-calpain was previously identified. Calpain is a calcium dependent-protease there are two isoforms, m-calpain mu-calpain, which differ concentration required for activation. m-Calpain needs about 10(-3) M ions, whereas 10(-5) M. When PS calpain were separately expressed COS cells by cDNA transfection then combined...

10.3892/ijmm.5.3.269 article EN International Journal of Molecular Medicine 2000-03-01

Leucine-rich alpha-2-glycoprotein (LRG) is a potential biomarker for disease activity and reflects mucosal healing in patients with ulcerative colitis (UC). However, only few studies have described detailed sensitivity analysis of LRG predicting patients. This study aimed to evaluate the association between endoscopic UC its predictability explore utility clinical application LRG.The diagnostic accuracy biomarkers, including LRG, was evaluated. All consecutive who underwent total colonoscopy...

10.1159/000534001 article EN cc-by-nc Inflammatory Intestinal Diseases 2023-01-01

5100 Background: S-1 is a novel oral anticancer agent, contains tegafur (FT), prodrug of 5-fluorouracil (5-FU), with 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) at molar ratio FT: CDHP: Oxo = 1:0.4:1. The purpose this study was to evaluate the efficacy safety in cytokine-refractory metastatic renal cell carcinoma (mRCC), examine relation between response mRNA expression levels 5-FU-related enzymes. Methods: Eligible patients had histologically confirmed diagnosis clear...

10.1200/jco.2009.27.15_suppl.5100 article EN Journal of Clinical Oncology 2009-05-20

A change in diagnosis from ulcerative colitis (UC) to Crohn's disease (CD) has been reported pediatric inflammatory bowel disease; however, only a few clinical characteristics and predictors of this diagnostic have reported. We aimed describe the patients with UC who underwent CD identify variables associated change.The medical records were followed up at National Center for Child Health Development between 2006 2019 retrospectively reviewed. Clinical data on phenotype, laboratory...

10.5223/pghn.2021.24.4.357 article EN Pediatric Gastroenterology Hepatology & Nutrition 2021-01-01

4703 Background: Bicalutamide (‘Casodex’) 80 mg (licensed dose in Japan) is being evaluated as part of combination therapy patients (pts) with previously untreated advanced prostate cancer an ongoing Japanese double-blind Phase III trial. Interim analysis after all pts had completed at least 6 months' follow-up (median 15 months) showed that first-line treatment bicalutamide a luteinizing hormone-releasing hormone (LHRH) agonist significantly improved the prostate-specific antigen...

10.1200/jco.2004.22.90140.4703 article EN Journal of Clinical Oncology 2004-07-15

The current histological evaluation of the effects endocrine therapy has difficulty in distinguishing pathologic degeneration caused by androgen ablation from residual poorly differentiated tumor. Therefore, we examined changes cell proliferation and apoptosis before after analyzed whether they correlated with differentiation.Between January 1986 December 1995, 52 patients clinical stage B2 C prostate cancer underwent radical prostatectomy neoadjuvant (median duration 3.8 months)....

10.1093/jjco/28.4.262 article EN Japanese Journal of Clinical Oncology 1998-04-01

5154 Background: Although the efficacy of CAB in advanced prostate cancer (PC) has been demonstrated by PCTCG and others, more evidence is required locally (Stage C) PC. The results a Japanese P III study bicalutamide Stage C/D PC suggested was better than monotherapy. When time to progression (TTP) evaluated C D separately, had significant benefits both stages stage were consistent with data. Thus, this exploratory analysis conducted evaluate thoroughly C. Methods: 205 untreated patients...

10.1200/jco.2007.25.18_suppl.5154 article EN Journal of Clinical Oncology 2007-06-20

<h3>Background</h3> Macrophage activation syndrome (MAS) is a severe, potentially life-threatening complication of pediatric rheumatic diseases. MAS occurs most often in children with systemic juvenile idiopathic arthritis (s-JIA) and less commonly lupus erythematosus (SLE), Kawasaki disease (KD) dermatomyositis (JDM). The hallmark includes uncontrolled dysfunctional immune responses involving continual expansion T lymphocytes macrophages, which turn lead to marked hypercytokinemia. However,...

10.1136/annrheumdis-2019-eular.6898 article EN Annals of the Rheumatic Diseases 2019-06-01

Bloom syndrome patients often develop severe gastrointestinal symptoms mainly caused by gastric tumors due to DNA repair disorder. Here, we report 31-year-old patient suffering persistent abdominal pain refractory gastroduodenal ulcers which required gastroduodenectomy. Various causes should be considered, and the accumulation of their reports is warranted.

10.1002/ccr3.6141 article EN cc-by Clinical Case Reports 2022-09-01
Coming Soon ...